Company SAB Biotherapeutics, Inc.

Equities

SABS

US78397T2024

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Nasdaq Other stock markets 11:01:48 2024-04-29 EDT			5-day change	1st Jan Change
4.2 ^USD	-1.17%		-4.33%	-38.91%

04-16	SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update	CI
04-02	HC Wainwright Adjusts Price Target on SAB Biotherapeutics to $6 From $10, Maintains Buy Rating	MT

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing fully human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The Company's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.

Number of employees: 57

USD in Million	2022	Weight	2023	Weight	Delta
Immunotheraphies 100.0 %	24	100.0 %	2	100.0 %	-90.63%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	24	100.0 %	2	100.0 %	-90.63%

Managers	Title	Age	Since
Eddie Sullivan FOU	Founder	58	21-10-21
Samuel Reich CEO	Chief Executive Officer	49	21-10-21
Michael King DFI	Director of Finance/CFO	63	23-10-29
Christoph Bausch COO	Chief Operating Officer	53	17-02-28
Alexandra Kropotova CTO	Chief Tech/Sci/R&D Officer	51	22-06-05
Melissa Ullerich IRC	Investor Relations Contact	-	20-02-29

Members of the board	Title	Age	Since
Christine Hamilton FOU	Founder	68	21-10-21
Jeffrey Spragens BRD	Director/Board Member	82	21-10-21
Erick Lucera BRD	Director/Board Member	57	23-04-02
David Link BRD	Director/Board Member	69	21-10-21
Samuel Reich CEO	Chief Executive Officer	49	21-10-21
William Polvino BRD	Director/Board Member	63	21-10-21
Eddie Sullivan FOU	Founder	58	21-10-21
Andrew Moin BRD	Director/Board Member	-	23-10-04
Katie Ellias BRD	Director/Board Member	-	11-19
Scott Giberson BRD	Director/Board Member	-	22-07-10

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	9,280,160	7,460,413 ( 80.39 %)	54,666 ( 0.5891 %)	80.39 %

Name	Equities	%	Valuation
RTW Investments LP 9.949 %	917,828	9.949 %	4 M $
BVF, Inc. 9.949 %	917,828	9.949 %	4 M $
Christine Hamilton 8.781 %	810,133	8.781 %	4 M $
Eddie Sullivan 5.671 %	523,230	5.671 %	2 M $
Marshall Wace LLP 4.970 %	458,528	4.970 %	2 M $
Sessa Capital IM LP 4.969 %	458,457	4.969 %	2 M $
Sessa Capital IM LP 4.969 %	458,457	4.969 %	2 M $
Helen K Ellias 3.097 %	285,714	3.097 %	1 M $
RA Capital Management LP 2.573 %	237,408	2.573 %	1 M $
Commodore Capital LP 1.985 %	183,175	1.985 %	831 615 $

Name	Equities	%	Valuation
LMR Partners LLP -	539,588	-	19 425 $
Shaolin Capital Management LLC -	371,641	-	13 379 $
Morgan Stanley Capital Services LLC -	150,089	-	5 403 $
Yakira Capital Management, Inc. -	108,485	-	3 905 $
UBS Securities LLC -	29,130	-	1 049 $
Walleye Capital LLC -	23,258	-	837 $
Wolverine Asset Management LLC -	22,810	-	821 $
Walleye Trading LLC -	15,505	-	558 $
NewEdge Advisors LLC -	1,072	-	39 $
Tower Research Capital LLC -	48	-	2 $

SAB Biotherapeutics, Inc.

2100 East 54th Street North

57104, Sioux Falls

http://www.sab.bio

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.25 USD

Average target price

15.5 USD

Spread / Average Target

+264.71%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SAB BIOTHERAPEUTICS, INC.	-38.91%	39.21M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.66%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-15.25%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-13.43%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+4.58%	13.68B
SAREPTA THERAPEUTICS, INC.	+35.44%	12.17B

Bio Therapeutic Drugs